Ke E Liu

7381405, Jun 3, 2008

Oct 15, 2002

10/531145

Ke Liu - Rockville MD, US
Steven A. Rosenberg - Potomac MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A01N 63/00
A61K 39/00
C12N 15/00
C12N 15/63
C07H 21/04

424 9321, 4353201, 435325, 435455, 536 235, 536 241, 4241841

The invention provides methods of preparing autologous T-lymphocytes for re-introduction into a patient having cancer, which method comprises obtaining peripheral blood mononuclear cells (PBMCs) from a patient immunized with an antigen of the cancer, stimulating the PBMCs with the antigen of the cancer in vitro, transducing the PBMCs with a retroviral vector, which (a) comprises and expresses a human interleukin-2 (IL-2) coding sequence operably linked to a retroviral promoter, (b) does not comprise an exogenously introduced gene that enables phenotypic selection, and (c) comprises a viral envelope that efficiently transduces CD8+ T-lymphocytes; compositions comprising cells obtained in accordance with such methods; and methods of treating a patient having cancer by administering to the patient cells obtained in accordance with such methods or compositions comprising same.

20130123214, May 16, 2013

Jul 19, 2011

13/810774

Wei Zheng - Potomac MD, US
Juan Jose Marugan - Gaithersburg MD, US
Ke Liu - Cambridge MD, US
Noel Terrence Southall - Chevy Chase MD, US
Christopher P. Austin - Potomac MD, US

The United States of America as Represented by the Secretary Department of HR - Rockville MD

A61K 31/355
A61K 31/724
A61K 45/06

514 58, 514458

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.

20170141535, May 18, 2017

Nov 13, 2015

14/941100

- Armonk NY, US
Ke Liu - Arlington VA, US
Devendra K. Sadana - Pleasantville NY, US
Volker J. Sorger - Alexandria VA, US

H01S 5/042
H01S 5/343
H01S 5/026
H01S 5/10

A plasmonic light source includes a substrate and a square nano-cavity formed on the substrate. The nano-cavity includes a quantum well structure. The quantum well structure includes III-V materials. A plasmonic metal is formed as an electrode on the square nano-cavity and is configured to excite surface plasmons with the quantum well structure to generate light. Complementary metal oxide semiconductor (CMOS) devices are formed on the substrate.

20170027903, Feb 2, 2017

Aug 17, 2016

15/239753

- Rockville MD, US
Juan Jose Marugan - Gaithersburg MD, US
Ke Liu - Cambridge MD, US
Noel Terrence Southall - Chevy Chase MD, US
Christopher P. Austin - Potomac MD, US

A61K 31/355
A61K 31/36
A61K 36/185
A61K 31/496
A61K 31/724
A61K 45/06

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol in combination with cyclodextrin to a patient in need thereof.

20150265571, Sep 24, 2015

May 13, 2015

14/711381

- ROCKVILLE MD, US
Juan Jose MARUGAN - GAITHERSBURG MD, US
Ke LIU - CAMBRIDGE MD, US
Noel Terrence SOUTHALL - CHEVY CHASE MD, US
Christopher P. AUSTIN - POTOMAC MD, US

A61K 31/355

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol in combination with cyclodextrin to a patient in need thereof.

20150234138, Aug 20, 2015

Oct 30, 2014

14/528392

Volker J. Sorger - Fairfax VA, US
Chenran Ye - Fairfax VA, US
Ke Liu - Arlington VA, US

The George Washington University - Washington DC

G02B 6/42

An electro-optical switch or router includes a semiconductor oxide substrate and first, second, and third semiconductor waveguides disposed on the semiconductor oxide substrate. The third waveguide includes a transparent conducting oxide layer, an oxide layer, a metal layer, and first and second electrodes coupled to the third waveguide. The electrodes are configured to bias and unbiased the third waveguide to effect optical switching in the electro-optical switch. The oxide layer is disposed between the transparent conducting oxide layer and the metal layer. The switch may further include a semiconductor layer disposed under the transparent conducting oxide layer between the transparent conducting oxide layer and the semiconductor oxide substrate. The first electrode may be coupled to the transparent conducting oxide layer. and the second electrode may be coupled to the metal layer.